Write in a clean editor, then format for Diabetes Obesity and Metabolism Now in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Diabetes Obesity and Metabolism Now is a peer-reviewed journal published by Wiley, covering Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Diabetes Obesity and Metabolism Now 12 (3): 45–58.
Formats any DOI in Diabetes Obesity and Metabolism Now style. No sign-up. |
| Publishes research in | Diabetes Treatment and Management Diabetes Management and Research Pancreatic function and diabetes Metabolism, Diabetes, and Cancer Diverse Scientific and Economic Studies |
| ISSN | 2688-8939 |
| Citation impact (2-yr) | 0.06 |
| h-index | 2 |
| Total citations | 16 |
| Open access | Yes |
| Top institutions publishing here | University of Nottingham |
| Journal website | dom-pubs.onlinelibrary.wiley.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Glucagon-like peptide receptor agonist (GLP-1) is a highly effective treatment to improve glucose levels, induced significant weight loss and reduce vascular events. However, ongoing concerns persists regarding its effect to cause loss of lean muscle mass in conjunction with weight loss. Loss of muscle mass in the context of weight loss and weight (fat mass)…
Diabetes, Obesity Metabolism (DOM) NOW – December 2023 Conclusive evidence have shown the cardiovascular benefits of semaglutide (1 mg weekly) in people with type 2 diabetes.1 Recent data have also confirmed the efficacy of high dose semaglutide (2.4 mg weekly) to induce significant weight loss in people without type 2 diabetes,2 but the cardiovascular benefits…
Obesity is the excessive growth of adipose tissue resulting from the chronic consumption of excess calories and is a recognised risk factor for developing cardio-metabolic diseases. There is however a significant variation in the size and expandibility of different adipose tissue in humans. The inability of adipose tissue to expand “safely” leads to ectopic fat…
Diabetes, Obesity Metabolism (DOM) NOW—November 2023 The dual GLP-1 and GIP agonist, Tirzepatide has been shown to induce significant weight loss in overweight/obese people with or without type 2 diabetes. Much of its efficacy was derived from The SURMOUNT program which included four global phase 3 trials NCT04184622 (SURMOUNT-1), NCT04657003 (SURMOUNT-2), NCT04657016 (SURMOUNT-3) and NCT04660643…
Tirzepatide, a dual GLP-1, GIP uni-molecular agonist had previously shown a significant ~22% weight loss in the SURMOUNT-1 pivotol trial and received FDA approval in 2022. The percentage weight loss observed in that study was indeed the largest weight loss seen in an anti-obesity, weight loss trial to date. Previous studies have also shown that…
